Tetraphase Pharmaceuticals Appoints Larry Tsai, M.D. to Chief Medical Officer
January 02 2018 - 4:35PM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage
biopharmaceutical company developing novel antibiotics to treat
life-threatening multidrug-resistant (MDR) infections, today
announced the promotion of Larry Tsai, M.D., Vice President,
Clinical Development, to Chief Medical Officer (CMO).
“Larry has provided significant expertise to the clinical team
throughout the IGNITE phase 3 program for eravacycline, our lead
antibiotic candidate, as well as in the early clinical development
of the Company’s pipeline programs,” said Guy Macdonald, President
and Chief Executive Officer of Tetraphase. “We are delighted to
welcome him to the management team. His leadership of the
clinical team will be important as we move forward with the new
drug application (NDA) regulatory process for IV eravacycline in
complicated intra-abdominal infections (cIAI) and as we await the
topline data readout for our IGNITE3 phase 3 trial in complicated
urinary tract infections (cUTI). We remain on track to report
IGNITE3 topline data this quarter.”
“I am excited to be taking on this leadership role at
Tetraphase,” said Dr. Tsai. “I look forward to continuing to work
with the rest of management to realize the full potential of
eravacycline as a treatment option for serious, and often
life-threatening, MDR gram-negative infections.”
Dr. Tsai joined the Company in 2014 as senior medical
director and became vice president, clinical development in 2015.
He has nearly 20 years of experience in healthcare and clinical
development. Prior to joining Tetraphase, he was vice president of
research and development, in addition to medical director, at Aeris
Therapeutics. Dr. Tsai is also a practicing physician at
Brigham and Women’s Hospital in Boston, Massachusetts and a
part-time instructor in medicine at Harvard Medical School.
Dr. Tsai holds a Bachelor of Science in Biology from Stanford
University and an M.D. from the Health Sciences and Technology
Program at Harvard Medical School. He is board certified in
critical care medicine, internal medicine and pulmonary
disease.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's pipeline
includes three antibiotic clinical candidates: eravacycline, which
has completed enrollment of phase 3 clinical trials, and TP-271 and
TP-6076, which are in phase 1 clinical trials. Please visit
www.tphase.com for more company information.
Investor Contacts:Argot PartnersMaeve
Conneighton206-899-4940maeve@argotpartners.com
Media Contact:Sam Brown Inc.Mike
Beyer312-961-2502Mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Sep 2023 to Sep 2024